Announced
MeiHua to acquire amino acid and HMO businesses of Kyowa Hakko Bio from Kirin for JPY10.5bn.
Synopsis
MeiHua, a China-based high-tech company centered on synthetic biology technology, agreed to acquire amino acid and HMO businesses of Kyowa Hakko Bio, a Japanese biotechnology and amino acids fermentation company, from Kirin, a Japanese beer and beverage holding company, for JPY10.5bn.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Vendor Team (12)
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
All rights reserved. Copyright © 2025 Datasite